CN117159702A - Application of lactoferrin capsule in regulating human immunity - Google Patents
Application of lactoferrin capsule in regulating human immunity Download PDFInfo
- Publication number
- CN117159702A CN117159702A CN202311205006.8A CN202311205006A CN117159702A CN 117159702 A CN117159702 A CN 117159702A CN 202311205006 A CN202311205006 A CN 202311205006A CN 117159702 A CN117159702 A CN 117159702A
- Authority
- CN
- China
- Prior art keywords
- parts
- lactoferrin
- capsule
- weight
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a lactoferrin capsule, which comprises the following raw materials in parts by weight: 8-25 parts of lactoferrin, 3-10 parts of immunoglobulin, 2-8 parts of ferrous gluconate, 4-9 parts of maltitol, 2-6 parts of isomaltooligosaccharide, 1-5 parts of magnesium stearate and 3-9 parts of alpha-cyclodextrin; the invention also provides application of the lactoferrin capsule in health care products for regulating human immunity, and the administration of the lactoferrin capsule can obviously enhance the immunity.
Description
Technical Field
The invention relates to the technical field of pharmaceutical preparations, in particular to application of a lactoferrin capsule in regulating human immunity.
Background
Lactoferrin is an iron ion binding glycoprotein, a naturally occurring protein in mammalian milk, and was originally isolated from bovine milk in the last 30 th century. Scientists then derive secondary particles from milk, tears, saliva, bile/pancreatic secretions, and neutrophil plasma in a variety of tissues in other humans and other mammals. Lactoferrin is a polypeptide chain containing 703 amino acid residues, the secondary structure of which includes an alpha-helix and a beta-sheet, the tertiary structure is two identical structures, N-and C-leaves, respectively, capable of splitting into 2 regions each, 1 iron ion is bound in a cleavage structure of 2 regions, and the iron-bound ligand is identical in the N-and C-leaves, the sites of which are highly conserved. Lactoferrin plays an important role in promoting iron absorption, inhibiting bacterial growth, resisting viruses, resisting cancers and the like, and has wide development prospect in the aspects of food health care, medical field and the like.
The biological activity of the lactoferrin product in the stomach and intestine can be influenced, and in order to keep the biological activity of the lactoferrin to the maximum extent, and overcome the killing of gastric acid, the health care function of the product on human body is enhanced, and the development of a new lactoferrin preparation product and the enhancement of the effect on regulating immunity are necessary.
Disclosure of Invention
Aiming at the technical problems, the invention aims to provide a novel lactoferrin capsule and application thereof in regulating immunity.
Therefore, the invention adopts the following technical scheme:
in a first aspect, the invention provides a lactoferrin capsule, comprising the following raw materials in parts by weight:
8-25 parts of lactoferrin, 3-10 parts of immunoglobulin, 2-8 parts of ferrous gluconate, 4-9 parts of maltitol, 2-6 parts of isomaltooligosaccharide, 1-5 parts of magnesium stearate and 3-9 parts of alpha-cyclodextrin.
The lactoferrin capsule comprises the following raw materials in parts by weight: 10-15 parts of lactoferrin, 3-7 parts of immunoglobulin, 2-5 parts of ferrous gluconate, 4-6 parts of maltitol, 3-5 parts of isomaltooligosaccharide, 2-4 parts of magnesium stearate and 3-6 parts of alpha-cyclodextrin.
The lactoferrin capsule comprises the following raw materials in parts by weight: 12-15 parts of lactoferrin, 4-6 parts of immunoglobulin, 3-4 parts of ferrous gluconate, 4-5 parts of maltitol, 3-4 parts of isomaltooligosaccharide, 2-3 parts of magnesium stearate and 3-4 parts of alpha-cyclodextrin.
The lactoferrin capsule further comprises 1-10 parts of lactobacillus reuteri and/or 1-10 parts of lactobacillus rhamnosus.
Further the lactobacillus reuteri is 2-6 parts and/or lactobacillus rhamnosus is 2-5 parts.
The lactobacillus reuteri or lactobacillus rhamnosus is freeze-dried powder, and the number of viable bacteria reaches 10 10 cfu/g or more.
The lactoferrin capsule further comprises 1-7 parts of vitamin C.
2-5 parts of vitamin C.
The lactoferrin capsule further comprises 2-5 parts of amino acids.
In a second aspect, the invention also provides an application of the lactoferrin capsule in health products for regulating human immunity.
Compared with the prior art, the invention has the following beneficial effects:
according to the lactoferrin capsule provided by the invention, the physiological activity of the lactoferrin reaching the intestinal tract can be obviously improved and the influence of NK cell activity can be improved by reasonably collocating the lactoferrin, the immunoglobulin, the ferrous gluconate, the maltitol, the isomaltooligosaccharide, the magnesium stearate and the alpha-cyclodextrin. The lactoferrin capsule of the invention can be further matched with probiotics such as lactobacillus reuteri, li Tangru bacillus, microbion C and the like, so that the double activities of immunity and microecology are effectively maintained, and the health care function of the product on human bodies is enhanced.
Detailed Description
The following claims are presented in further detail in connection with the detailed description, but are not to be construed as limiting the invention, as any person who makes a limited number of modifications within the scope of the claims is within the scope of the claims.
Example 1
The lactoferrin capsule comprises the following raw materials in parts by weight: 25 parts of lactoferrin, 8 parts of immunoglobulin, 3 parts of ferrous gluconate, 4 parts of maltitol, 3 parts of isomaltooligosaccharide, 4 parts of magnesium stearate and 5 parts of alpha-cyclodextrin.
Example 2
The lactoferrin capsule comprises the following raw materials in parts by weight: 20 parts of lactoferrin, 5 parts of immunoglobulin, 4 parts of ferrous gluconate, 5 parts of maltitol, 4 parts of isomaltooligosaccharide, 3 parts of magnesium stearate and 4 parts of alpha-cyclodextrin.
Example 3
The lactoferrin capsule comprises the following raw materials in parts by weight: 10 parts of lactoferrin, 3 parts of immunoglobulin, 2 parts of ferrous gluconate, 4 parts of maltitol, 3 parts of isomaltooligosaccharide, 2 parts of magnesium stearate, 3 parts of alpha-cyclodextrin and 3 parts of lactobacillus reuteri.
Example 4
The lactoferrin capsule comprises the following raw materials in parts by weight: the material comprises the following raw materials in parts by weight: 13 parts of lactoferrin, 4 parts of immunoglobulin, 3 parts of ferrous gluconate, 4 parts of maltitol, 3 parts of isomaltooligosaccharide, 3 parts of magnesium stearate, 3 parts of alpha-cyclodextrin and 2 parts of vitamin C.
Example 5
The lactoferrin capsule comprises the following raw materials in parts by weight: the material comprises the following raw materials in parts by weight: 13 parts of lactoferrin, 4 parts of immunoglobulin, 3 parts of ferrous gluconate, 4 parts of maltitol, 3 parts of isomaltooligosaccharide, 3 parts of magnesium stearate, 3 parts of alpha-cyclodextrin and 2 parts of amino acid.
Example 6
The lactoferrin capsule comprises the following raw materials in parts by weight: 20 parts of lactoferrin, 5 parts of immunoglobulin, 4 parts of ferrous gluconate, 5 parts of maltitol, 4 parts of isomaltooligosaccharide, 3 parts of magnesium stearate, 4 parts of alpha-cyclodextrin, 4 parts of bacillus dysenteriae Li Tangru and 3 parts of vitamin C.
Example 7
The lactoferrin capsule comprises the following raw materials in parts by weight: the material comprises the following raw materials in parts by weight: 13 parts of lactoferrin, 4 parts of immunoglobulin, 3 parts of ferrous gluconate, 4 parts of maltitol, 3 parts of isomaltooligosaccharide, 3 parts of magnesium stearate, 3 parts of alpha-cyclodextrin, 2 parts of vitamin C and 2 parts of amino acid.
Example 8
The lactoferrin capsule comprises the following raw materials in parts by weight: the material comprises the following raw materials in parts by weight: 13 parts of lactoferrin, 4 parts of immunoglobulin, 3 parts of ferrous gluconate, 4 parts of maltitol, 3 parts of isomaltooligosaccharide, 3 parts of magnesium stearate, 3 parts of alpha-cyclodextrin, 5 parts of lactobacillus reuteri and 2 parts of amino acid.
Example 9
The lactoferrin capsule comprises the following raw materials in parts by weight: the material comprises the following raw materials in parts by weight: 13 parts of lactoferrin, 4 parts of immunoglobulin, 3 parts of ferrous gluconate, 4 parts of maltitol, 3 parts of isomaltooligosaccharide, 3 parts of magnesium stearate, 3 parts of alpha-cyclodextrin, 4 parts of vitamin C, 4 parts of lactobacillus reuteri and 3 parts of amino acid.
Comparative example 1
The lactoferrin capsule comprises the following raw materials in parts by weight: 4 parts of lactoferrin, 3 parts of ferrous gluconate, 4 parts of maltitol, 3 parts of isomaltooligosaccharide, 4 parts of magnesium stearate and 5 parts of alpha-cyclodextrin.
Comparative example 2
The lactoferrin capsule comprises the following raw materials in parts by weight: 5 parts of lactoferrin, 1 part of immunoglobulin, 3 parts of isomaltooligosaccharide, 2 parts of magnesium stearate, 3 parts of alpha-cyclodextrin and 3 parts of lactobacillus reuteri.
Comparative example 3
The lactoferrin capsule comprises the following raw materials in parts by weight: 10 parts of lactoferrin, 4 parts of immunoglobulin, 3 parts of magnesium stearate, 3 parts of alpha-cyclodextrin, 1 part of vitamin C and 4 parts of lactobacillus reuteri.
Test examples investigation of the immune function of mice by the inventive product
1. Test materials and methods
SPF-grade Kunming male mice were 130, weighing 18-22g, and were divided into 1 group for every 10 animals, for a total of 13 groups. Each group was randomly divided into distilled water blank, test 1-9 (examples 1-9), control 1-3 (comparative examples 1-3), and 10 mice per group.
The lactoferrin capsule samples prepared in examples 1-9 and comparative examples 1-3 were prepared into aqueous solutions, and distilled water was administered to the test animals in equal volumes to the blank group, respectively, and the test animals were subjected to intragastric administration once a day, with the intragastric administration volume of 4ml, for 30 consecutive days.
2. Experimental method
1. Effect of lactoferrin on mouse body Mass
After oral administration of lactoferrin in different dosage groups to mice for 1 month, the weight gain value of each dosage group is subjected to a variance alignment test, so that the variance alignment requirement is met, and statistical treatment is performed by a two-by-two comparison method of average numbers between a plurality of experimental groups and a control group in a single-factor variance analysis method.
Determination of NK cell Activity (lactate dehydrogenase assay)
The cervical dislocation of the tested mice is killed, spleens are aseptically taken, cell suspensions are prepared, the mice are washed for 2 times by Hanks liquid, the mice are centrifuged for 10min, the cell suspensions are sprung by discarding the supernatant, 0.5mL of sterile water is added for 20 seconds, 0.5mL of Hanks liquid which is 2 times and 8mL of Hanks liquid are added after red blood cells are lysed, the mice are centrifuged for 10min, 1mL of RPMI 1640 complete culture solution containing 10% calf serum is used for resuspension, the mice are diluted by 1% glacial acetic acid and counted, the living cells are counted by using the dyeing of the tepanolen (the living cells are more than 95 percent), and the cell concentration is adjusted to be 2 multiplied by 10 10 At a ratio of one per ml, which is effector cells, YAC-1 cells well grown 24h after passage were taken and adjusted to 4X 10 in cell concentration with RPMI 1640 complete medium 10 The number of cells per ml, which is the target cell; taking target cells and effector cells of 100U l (the effective target ratio is 50:1) respectively, and adding the target cells and the effector cells into a U-shaped 96-well culture plate; target cells naturally released Kong Jiaba cells and culture medium 100u l each, target cells maximally released Kong Jiaba cells and 2.5% tr iton 100u l each; three parallel wells were set up for each, incubated for 4h at 37℃in a 5% carbon dioxide incubator, then 96 well plates were centrifuged at 1500r/min for 5min, 100u L supernatant was aspirated from each well into a flat bottom 96 well plate, and LDH matrix solution 100u L was added, reacted for 3-10min at room temperature with 1 mol/L HCl 30u L added to each well, and Optical Density (OD) was measured at 490nm in an microplate reader.
NK cell Activity= [ (reaction well OD-natural release well OD)/(maximum release well OD-natural release well OD) ]. Times.100%.
3. Test results
(1) Effect of lactoferrin on mouse body Mass
TABLE 1 Effect of lactoferrin on mouse body mass
| Group of | Weight gain/g |
| Test group 1 | 6.75±1.21 |
| Test group 2 | 6.15±1.46 |
| Test group 3 | 7.28±2.20 |
| Test group 4 | 7.55±2.74 |
| Test group 5 | 7.98±2.59 |
| Test group 6 | 8.25±1.93 |
| Test group 7 | 8.78±2.68 |
| Test group 8 | 8.86±3.17 |
| Test group 9 | 9.43±3.25 |
| Control group 1 | 2.73±0.76 |
| Control group 2 | 3.35±1.12 |
| Control group 3 | 3.75±1.38 |
| Blank control group | 0.48±0.16 |
After oral administration of lactoferrin in different dose groups to mice for 1 month, the body weight of each test group was significantly increased compared to the control group.
(2) Influence of the product of the invention on the NK cell activity of mice
The influence of the lactoferrin capsule sample on the NK cell activity of the mice is shown in Table 2, and the NK cell activity of the mice in the test group is greatly improved compared with that in the control group, which indicates that the NK cell activity of the mice is obviously improved compared with that in the control group after the lactoferrin capsule sample is taken.
TABLE 2 Effect of lactoferrin capsules on NK cell Activity in mice (x.+ -. S)
| Group of | NK cell Activity/% |
| Test group1 | 81.6±4.8 |
| Test group 2 | 82.6±5.6 |
| Test group 3 | 88.9±4.7 |
| Test group 4 | 87.6±4.2 |
| Test group 5 | 85.8±3.9 |
| Test group 6 | 89.6±5.1 |
| Test group 7 | 91.6±2.9 |
| Test group 8 | 92.7±3.8 |
| Test group 9 | 96.3±5.2 |
| Control group 1 | 42.2±2.1 |
| Control group 2 | 44.3±3.3 |
| Control group 3 | 51.7±5.6 |
| Blank control group | 30.7±3.4 |
After the mice are orally administrated with lactoferrin liquid for 30 days, the tested object can enhance NK cell activity and has the capability of enhancing cell immunity.
The above examples are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above examples, and any other changes, modifications, substitutions, combinations, and simplifications that do not depart from the spirit and principle of the present invention should be made in the equivalent manner, and the embodiments are included in the protection scope of the present invention.
Claims (10)
1. The lactoferrin capsule is characterized by comprising the following raw materials in parts by weight: 8-25 parts of lactoferrin, 3-10 parts of immunoglobulin, 2-8 parts of ferrous gluconate, 4-9 parts of maltitol, 2-6 parts of isomaltooligosaccharide, 1-5 parts of magnesium stearate and 3-9 parts of alpha-cyclodextrin.
2. Lactoferrin capsule as in claim 1, characterized in that it comprises the following raw materials in parts by weight: 10-15 parts of lactoferrin, 3-7 parts of immunoglobulin, 2-5 parts of ferrous gluconate, 4-6 parts of maltitol, 3-5 parts of isomaltooligosaccharide, 2-4 parts of magnesium stearate and 3-6 parts of alpha-cyclodextrin.
3. Lactoferrin capsule in accordance with claim 1, characterized in that it comprises the following raw materials in parts by weight: 12-15 parts of lactoferrin, 4-6 parts of immunoglobulin, 3-4 parts of ferrous gluconate, 4-5 parts of maltitol, 3-4 parts of isomaltooligosaccharide, 2-3 parts of magnesium stearate and 3-4 parts of alpha-cyclodextrin.
4. A lactoferrin capsule as in claims 1-3, further comprising 1-10 parts of lactobacillus reuteri and/or 1-10 parts of lactobacillus rhamnosus.
5. The lactoferrin capsule of claim 4, wherein the lactobacillus reuteri is 2-6 parts and/or lactobacillus rhamnosus is 2-5 parts.
6. Lactoferrin capsule in accordance with claim 4 or 5, characterized in that said lactobacillus reuteri or lactobacillus rhamnosus is a lyophilized powder, the number of viable bacteria reaching 10 10 cfu/g or more.
7. Lactoferrin capsule in accordance with claims 1-6, characterized in that it further comprises vitamin C1-7 parts.
8. Lactoferrin capsule in accordance with claim 7, characterized in that said vitamin C is 2-5 parts.
9. The lactoferrin capsule of claim 7, further comprising 2-5 parts of amino acids.
10. Use of the lactoferrin capsule of claims 1-9 in health products for regulating human immunity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311205006.8A CN117159702A (en) | 2023-09-19 | 2023-09-19 | Application of lactoferrin capsule in regulating human immunity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311205006.8A CN117159702A (en) | 2023-09-19 | 2023-09-19 | Application of lactoferrin capsule in regulating human immunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117159702A true CN117159702A (en) | 2023-12-05 |
Family
ID=88935308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311205006.8A Pending CN117159702A (en) | 2023-09-19 | 2023-09-19 | Application of lactoferrin capsule in regulating human immunity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117159702A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08253423A (en) * | 1995-01-19 | 1996-10-01 | Tokushu Meneki Kenkyusho:Kk | Food and medicinal granule containing lactoferrin and their production |
| AU5957799A (en) * | 1994-10-28 | 2000-02-17 | Metagenics, Inc. | Compositions and methods for human gastrointestinal health |
| KR20020024902A (en) * | 2000-09-27 | 2002-04-03 | 장동한 | Agent of immunological enhancement comprising colostral fractions as active ingredient, method of the preparation for the same and its use |
| US20130280239A1 (en) * | 2010-11-15 | 2013-10-24 | Nestec S.A. | Array of complementary infant/young child nutritional compositions |
| CN103734745A (en) * | 2013-12-18 | 2014-04-23 | 武汉市元大生物科技有限公司 | Method for preparing compound microcapsule of high-concentration lactoferrin and lactobacillus acidophilus |
| CN107712050A (en) * | 2017-09-15 | 2018-02-23 | 安徽科技学院 | One kind addition sialic acid and digestible premature labor baby milk powder and preparation method thereof |
| CN108208838A (en) * | 2018-03-09 | 2018-06-29 | 北京素维生物科技有限公司 | A kind of taste masking composition and application thereof |
| CN108244252A (en) * | 2018-03-13 | 2018-07-06 | 汉臣氏（沈阳）儿童制品有限公司 | Probiotics multielement protein powder and preparation method thereof |
| CN109498590A (en) * | 2018-11-30 | 2019-03-22 | 江苏天美健大自然生物工程有限公司 | Lactoferrin capsule and preparation method thereof |
| CN110115387A (en) * | 2018-02-05 | 2019-08-13 | 常州英莱克斯生物工程有限公司 | A kind of lactoferrin piece health food and its production method |
-
2023
- 2023-09-19 CN CN202311205006.8A patent/CN117159702A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5957799A (en) * | 1994-10-28 | 2000-02-17 | Metagenics, Inc. | Compositions and methods for human gastrointestinal health |
| JPH08253423A (en) * | 1995-01-19 | 1996-10-01 | Tokushu Meneki Kenkyusho:Kk | Food and medicinal granule containing lactoferrin and their production |
| KR20020024902A (en) * | 2000-09-27 | 2002-04-03 | 장동한 | Agent of immunological enhancement comprising colostral fractions as active ingredient, method of the preparation for the same and its use |
| US20130280239A1 (en) * | 2010-11-15 | 2013-10-24 | Nestec S.A. | Array of complementary infant/young child nutritional compositions |
| CN103734745A (en) * | 2013-12-18 | 2014-04-23 | 武汉市元大生物科技有限公司 | Method for preparing compound microcapsule of high-concentration lactoferrin and lactobacillus acidophilus |
| CN107712050A (en) * | 2017-09-15 | 2018-02-23 | 安徽科技学院 | One kind addition sialic acid and digestible premature labor baby milk powder and preparation method thereof |
| CN110115387A (en) * | 2018-02-05 | 2019-08-13 | 常州英莱克斯生物工程有限公司 | A kind of lactoferrin piece health food and its production method |
| CN108208838A (en) * | 2018-03-09 | 2018-06-29 | 北京素维生物科技有限公司 | A kind of taste masking composition and application thereof |
| CN108244252A (en) * | 2018-03-13 | 2018-07-06 | 汉臣氏（沈阳）儿童制品有限公司 | Probiotics multielement protein powder and preparation method thereof |
| CN109498590A (en) * | 2018-11-30 | 2019-03-22 | 江苏天美健大自然生物工程有限公司 | Lactoferrin capsule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110964657B (en) | Bifidobacterium lactis BL-99 capable of improving immunity and application thereof | |
| US11911423B2 (en) | Bifidobacterium lactis BL-99 and application thereof | |
| CN110959676B (en) | Fermented milk product containing bifidobacterium lactis and application thereof | |
| JP6985342B2 (en) | Bifidobacterium Lactis GKK2, a composition containing it, and its use for allergic asthma amelioration | |
| KR101640744B1 (en) | Macromolecular polysaccharide binder conjugated Lactobacillus rhamnosus RHT-3201, and use thereof in prevention and treatment of atopic dermatitis | |
| CN114774315B (en) | Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product | |
| EP1854467A1 (en) | Composition for immune activation | |
| CN112940970B (en) | Intestinal probiotics and application thereof in treating tumors and replacing antibiotics | |
| WO2010001509A1 (en) | Novel lactic acid bacterium having high immunoglobulin-a-inducing ability | |
| JP5337535B2 (en) | NK activity enhancer | |
| CN112375722B (en) | Lactobacillus casei LC-12 for improving allergy, and product and application thereof | |
| CN114468306A (en) | Application of bacillus coagulans BC99 in preparing colitis relieving product or immunoregulation product | |
| TWI754929B (en) | Use of lactic acid bacteria for increasing resistance against enterovirus 71 | |
| CN117327606A (en) | A Bifidobacterium longum strain and its preparation method and use | |
| JP5209294B2 (en) | Interleukin 12 production promoter | |
| CN111728030B (en) | Sucrose-free yogurt with immunity improving function and long shelf life at normal temperature and preparation method thereof | |
| CN111743158B (en) | Probiotic tablet with function of enhancing immunity and preparation method thereof | |
| TW201315475A (en) | Composition and use of Lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases | |
| CN117159702A (en) | Application of lactoferrin capsule in regulating human immunity | |
| CN113337440A (en) | Lactobacillus salivarius MG-587 and application thereof | |
| RU2491336C1 (en) | Bifidobacterial and lactobacillary consortium for preparing bacterial preparations and dietary supplements for correcting gastrointestinal microflora in individuals of fourteen and older, and method for preparing it, dietary supplement for correcting gastrointestinal microflora in individuals of fourteen and older and bacterial preparation for treating dysbiotic gastrointestinal conditions in individuals of fourteen and older | |
| TWI817332B (en) | Use of lactic acid bacteria for increasing resistance against enterovirus 71 | |
| RU2176668C1 (en) | Strain of bacterium lactobacillus acidophilus nv ep 317/402 "narine" tnci used for preparing curative-prophylactic preparations for intestine microflora normalization | |
| EP1894995A4 (en) | Irilis biopreparation based on bacillus-strain bacteria, bacillus subtilis and bacillus licheniformis contained therein | |
| JP7663240B2 (en) | Intestinal immunity stimulator and IgA production promoter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |